Systemic Pharmacokinetics of Everolimus Eluted from the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy

Journal of the American College of Cardiology

Volumn 66, Issue 21, 2015, Pages 2467-2469

  Rizik, David G ^b   Cannon, Louis ^b   Stone, Gregg W ^a   Kennedy, Maureen ^b   Piard Ruster, Karine ^b   Staehr, Peter ^b   Ellis, Stephen G ^b   Kereiakes, Dean J ^b  

^a NewYork Presbyterian Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS;

ADULT; AREA UNDER THE CURVE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; HUMAN; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; BIODEGRADABLE IMPLANT; DRUG ELUTING STENT; MIDDLE AGED; PROSPECTIVE STUDY; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; AGED; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE SCAFFOLDS;

EID: 84961059965     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.09.030     Document Type: Letter

References (5)

1. D. Kereiakes, S.G. Ellis, J.J. Popma, and et al. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial Am Heart J 170 2015 641 651
2. Q. Wang, W. Pierson, P. Sood, and et al. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus-eluting coronary stent system J Interv Cardiol 23 2010 26 32
3. M. Wiemer, A. Seth, P. Chandra, and et al. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study Am Heart J 156 2008 751.e1 751.e7
4. R.C. Starling, J.M. Hare, P. Hauptman, and et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling Am J Transplant 4 2004 2126 2131
5. A. O'Donnell, S. Faivre, H.A. Burris 3rd, and et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595